| Detected | Trial | Change |
|---|---|---|
| 2026-05-21 | NCT07597564 Dose-Response Interaction of Metoprolol and Sufentanil for Attenuating Hemodynamic… |
Primary endpoint(s) modified |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-05-19 | NCT07597564 Dose-Response Interaction of Metoprolol and Sufentanil for Attenuating Hemodynamic… | Phase 4 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT07445789 | SMART-VERAPAF: Self-MAnagement and Random Therapy With VERApamil or Metoprolol in… | Atrial Fibrillation (AF) | Not Yet Recruiting |
| NCT07597564 | Dose-Response Interaction of Metoprolol and Sufentanil for Attenuating Hemodynamic… | General Anesthesia; Tracheal Intubation | Not Yet Recruiting |
| Phase 2 | |||
| NCT00840047 | Methionine PET/CT Studies In Patients With Cancer | Brain Tumors and/or Solid Tumors Including | Active, Not Recruiting |
| Not specified | |||
| NCT07568574 | Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes | Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes | Enrolling by Invitation |